Akari Therapeutics (AKTX, Financial) has unveiled a corporate update video that highlights leadership changes within the company. The video prominently features Abizer Gaslightwala, who has recently taken on the role of President and Chief Executive Officer. This development marks a significant transition for the company as Gaslightwala steps into his new position.
Akari Therapeutics, known for its focus on developing treatments for rare and orphan diseases, has positioned Gaslightwala to lead its strategic direction. The update video aims to communicate the company's current priorities and future plans under the new leadership, offering insights into how Gaslightwala intends to drive the company's growth and innovation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Akari Therapeutics PLC (AKTX, Financial) is $80.00 with a high estimate of $80.00 and a low estimate of $80.00. The average target implies an upside of 6,150.00% from the current price of $1.28. More detailed estimate data can be found on the Akari Therapeutics PLC (AKTX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Akari Therapeutics PLC's (AKTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
